NBY earnings

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and

Net product sales increased 13% over the prior year driven by higher sales of Avenova®-branded products through OTC channels and branded wound care products Sales and marketing expenses declined 15% reflecting continued digital marketing optimization Ordered product sales for Avenova-branded products on Amazon.com reached new all-time records in March and April Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three months ended March 31, 2024 and provides a business update. "Net product sales growth of 13% versus the prior year was driven by higher sales of Avenova-branded products through online

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time:  Thursday, May 9, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

Q4 net sales from the eyecare and wound care segment grew 10% over the prior year with higher sales from the Avenova® physician dispensed and OTC channels, and from branded wound care products Sales and marketing expenses for the quarter declined 27% reflecting digital marketing optimization Divestiture of skincare segment expected to bolster cash position and reduce operating expenses Continued execution on eyecare growth strategy including recent co-marketing partnership Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time:   Tuesday, March 26, 4:30 p.m. ET / 1:30 p.m. PT       Pre-Registration:   Participants can pre-register for the conference call here:           Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, inc

DERMAdoctor sale reduces operating expenses and bolsters cash NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the Company has entered into an agreement to sell its DERMAdoctor® skincare business including all product inventory for approximately $1.0 million in cash. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. "This sale will reduce our quarterly operating expenses and provide us with much-needed cash during this challenging capital market environment. It also streamlines our business by p

Net product revenue from Avenova®-branded eyecare products grew 7% year-over-year, reflecting an increased contribution from the physician dispensed channel Sales and marketing expenses declined 7% versus the prior year through continued optimized digital marketing programs Operating loss for the first nine months of 2023 narrowed by 16% from the prior year Marketing activities are underway to promote differentiated, high-quality Avenova Allograft to a broad target audience of U.S. eyecare specialists Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and nine months ended September 30, 2023

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Thursday, November 9, 4:30 p.m. ET / 1:30 p.m. PT     Pre-Registration: Participants can pre-register for the conference call here:       Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, incl

Net product revenue of $4.6 million increased 26% over the prior-year quarter Wound care sales of $1.3 million mark a record quarterly high Sales and marketing expenses reduced by 16% through optimized digital marketing programs Operating loss decreased by 37% year-over-year Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and six months ended June 30, 2023 and provides a business update. "Net product revenue reached $4.6 million for the quarter, up 26% from the prior year as we benefited from a particularly strong quarter in our wound care segment," said Justin Hall, NovaBay CEO. "We co

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2023 after market close on Thursday, August 10, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time:   Thursday, August 10, 4:30 p.m. ET / 1:30 p.m. PT       Pre-Registration:   Participants can pre-register for the conference call here:           Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, in

Sales of eyecare products increased with higher sales of Avenova Spray related companion products Sales and marketing spend reduced by 17% through optimized digital marketing programs Launched DERMAdoctor® Comfort + Joy Psoriasis Therapeutic Moisturizing Cream Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three months ended March 31, 2023 and provides a business update. "Net product revenue from our Avenova-branded eyecare products increased over the prior year driven by higher sales of Avenova Spray sold through our physician-dispensed channel and by increased interest in our Avenova companio

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three months ended March 31, 2023 after market close on Thursday, May 11, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time:   Thursday, May 11, 4:30 p.m. ET / 1:30 p.m. PT       Pre-Registration:   Participants can pre-register for the conference call here:           Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-re

Product sales increased 15% for the quarter and 41% for the year, driven by increasingly diversified revenue streams Wound care revenue increased 143% year over year Digital marketing program optimization continued to drive higher product sales on lower marketing spend Eyecare portfolio recently expanded with the introduction of the Avenova® oral supplement and Eyeganics Organic Tears Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and 12 months ended December 31, 2022 and provides a business update. Financial results for 2022 include DERMAdoctor®, which NovaBay acquired on November 5, 2021.

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and 12 months ended December 31, 2022 after market close on Thursday, March 30, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Thursday, March 30, 4:30 p.m. ET / 1:30 p.m. PT         Pre-Registration: Participants can pre-register for the conference call here:     Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the ca

Product revenue growth of 69% resulting from diversified revenue streams, including DERMAdoctor products in the third quarter of 2022 DERMAdoctor® skincare product sales at highest level since the acquisition a year ago Achieved continued online Avenova® Spray unit growth Optimized digital marketing programs drove higher sales on lower expenses Conference call begins at 4:30 p.m. Eastern Time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and nine months ended September 30, 2022 and provides a business update. Financial results for the first nine months of 2022 include DERMAdoctor, which NovaBay acquired on November 5, 2021. "Revenues grew

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and nine months ended September 30, 2022 after market close on Monday, November 14, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Monday, November 14, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

Product revenue increased by 43% year-over-year, fueled by a growing product portfolio in the eyecare and skincare markets Continued year-over-year growth in online Avenova® Spray unit sales Launched seven new OTC Avenova and DERMAdoctor® products since the beginning of 2022 Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and six months ended June 30, 2022 and provides a business update. Financial results for the first six months of 2022 include the operations of the DERMAdoctor business, which was acquired on November 5, 2021. "The strategy to expand and diversify our portfolio of high-quality

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2022 after market close on Thursday, August 11, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time:   Thursday, August 11, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration:   Participants can pre-register for the conference call here:   Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

Avenova® Spray unit sales increased 15% with record-high units sold through the OTC channel Announced launch of two next-generation OTC DERMAdoctor products this week building on momentum of top-selling collections, bringing new OTC product introductions to five since the beginning of 2022 Increased total sales by 46% by executing on growth strategy including the DERMAdoctor acquisition to build on established presence in the eyecare and skincare markets Benefitted from operational synergies through consolidated warehouse operations Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three months ended

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three months ended March 31, 2022 after market close on Thursday, May 12, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time:   Thursday, May 12, 4:30 p.m. ET / 1:30 p.m. PT       Pre-Registration:   Participants can pre-register for the conference call here:     Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time

Fourth quarter net product revenue increased 40% on record Avenova spray unit sales 2021 Avenova spray net revenue increased 15% on 31% growth in unit sales 2020 net product revenue boosted by $3.1 million in non-recurring PPE product sales Company executing on growth strategy with DERMAdoctor acquisition Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and 12 months ended December 31, 2021 and provides a business update. Financial results include the operations of the acquired DERMAdoctor business beginning November 5, 2021. "NovaBay closed out an eventful year on a high note with fourth quar

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and 12 months ended December 31, 2021 after market close on Tuesday, March 29, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, March 29, 4:30 p.m. ET / 1:30 p.m. PT     Pre-Registration: Participants can pre-register for the conference call here:       Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after

DERMAdoctor acquisition significantly expands NovaBay's presence in the large and lucrative skincare market DERMAdoctor transaction is immediately accretive to NovaBay's earnings with expected profitability within one year Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and nine months ended September 30, 2021 and provides a business update. "This has been a great year for NovaBay. Avenova revenue has increased by 16% over the same period last year and we've cut our net loss per share in half. Unit sales have reached an all-time high as more people are using Avenova than ever before. Most importantl

Company to hold third quarter 2021 earnings call on November 11 and will discuss plans for the combined companies NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces the closing of the previously announced acquisition of DERMAdoctor, LLC. The Company also announced that it will report financial results for the third quarter 2021 on Thursday November 11, 2021 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. "Now that we have officially closed on the acquisition, it is time to start realizing synergies and growing our combined businesses. On our conference call later this week we will discuss the many benefits we see from the DERMAdoctor ac

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that management will discuss its acquisition of DERMAdoctor on an investment community conference call and webcast with accompanying slide presentation today, Wednesday, September 29, 2021 beginning at 4:30 p.m. Eastern time. Date/Time: Wednesday, September 29, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.  

Acquisition has the potential to double topline revenue in 2022 Operational synergies and diversified product portfolio expected to drive profitability Conference Call Wednesday at 1:30 p.m. Pacific time NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces it has entered into a definitive agreement to acquire DERMAdoctor, LLC, a privately-held company that commercializes dermatologist-developed skincare products, including all of its inventory, products and intellectual property, for a purchase price of $15.0 million, comprised of $12.0 million in cash at closing and up to an additional $3 million in earnout payments contingent upon the DERMAdoctor business achieving predetermined financi

Fourth consecutive quarter of record Avenova® OTC unit sales with record OTC revenue of $1.3 million Avenova availability expands to more than half of all CVS stores across the U.S. ImprimisRx begins promoting prescription Avenova to eyecare professionals nationwide Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and six months ended June 30, 2021 and provides a business update. "Unit sales reached a new quarterly record as more people than ever before are using and benefitting from Avenova," said Justin Hall, President and CEO of NovaBay Pharmaceuticals. "We also are reporting record revenue f

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces it will report financial results for the three and six months ended June 30, 2021 after market close on Thursday, August 12, 2021 and will hold an investment community conference call that day at 4:30 p.m. Eastern time. Date/Time: Thursday, August 12, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.  

Over-the counter ("OTC") Avenova® revenue topped $1 million for the first time with record unit sales Cash and cash equivalents of $10.5 million as of March 31, 2021 Extending the Avenova product line with complementary products Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three months ended March 31, 2021 and provides a business update. "Our focus on the OTC channel is paying off as Avenova direct-to-consumer quarterly revenue exceeded $1 million for the first time with unit sales setting a new record. The OTC channel accounted for approximately 79% of Avenova revenue for the quarter, up from 51

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and twelve months ended December 31, 2020 and provides a business update. “Avenova unit sales for the fourth quarter reached a new record, driven primarily by online orders as well as through our physician dispensed channel,” said Justin Hall, President and CEO of NovaBay Pharmaceuticals. “Product revenue for the fourth quarter increased 10% over the prior year quarter. For the full year 2020, product revenue grew an impressive 51%, which included tapping our international health supply network early in the pandemic to sell personal protection equipment